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Abstract  
Dendritic cells (DC) are critical actors in the initiation of primary immune responses 
and regulation of self-tolerance. The steroid sex hormone 17ß-œstradiol (E2) has been shown 
to promote the differentiation of DCs from bone marrow (BM) precursors in vitro. However, 
the estrogen receptor (ER) involved in this effect has not yet been characterized. Using 
recently generated ER!- or ERß-deficient mice, we investigated the role of ER isotypes in 
DC differentiation and acquisition of effector functions. We report that estrogen-dependent 
activation of ER!, but not ERß, is required for normal DC development from BM precursors 
cultured with GM-CSF. We show that reduced numbers of DCs were generated in the absence 
of ER!-activation and provide evidence for a cell autonomous function of ER!-signaling in 
DC differentiation. ER!-deficient DCs were phenotypically and functionally distinct from 
wild-type DCs generated in the presence of estrogens. In response to microbial components, 
ER!-deficient DCs failed to upregulate MHC class II and CD86 molecules, which could 
account for their reduced capacity to prime naive CD4
+
 T lymphocytes. Although, they 
retained the ability to express CD40 and to produce pro-inflammatory cytokines (e.g. IL-12, 
IL-6)  upon TLR engagement, ER!-deficient DCs were defective in their ability to secrete 
such cytokines in response to CD40-CD40L interactions. Combined, these results provide the 
first genetic evidence that ER! is the main receptor regulating estrogen-dependent DC 
differentiation in vitro and acquisition of their effector functions.  
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Introduction 
Dendritic cells (DC) are the major class of antigen presenting cells (APC). They play a 
central role in the initiation and coordination of the innate and adaptive immune responses by 
integrating signals from pathogens, cytokines and T cells. DC activation can be induced by a 
variety of signal, such as microbial or viral products which are directly recognized by 
members of the Toll-like receptor (TLR) family (1). Upon activation, DCs mature into potent 
APCs expressing high levels of MHC molecules and costimulatory molecules (CD80/CD86, 
CD40)  and secrete immunomodulatory cytokines, such as IL-12, IL-6 and IL-10 that control 
the expansion and differentiation of naive T cells into effectors (2-4). Although, IL-12 
synthesis by DCs can be initiated by microbial signals, it requires reciprocal signaling from T 
cells for optimal production (5, 6). This cellular dialogue is mainly dependent on the 
interactions between CD40 expressed by DCs and its ligand CD154 (CD40L) which is 
expressed by CD4
+
 T cells following TCR stimulation (7). 
DCs represent an extremely plastic and versatile cell type, which plays crucial role not 
only in the initiation and control of immunity and tolerance, but can also contribute to the 
induction of pathological situations such as autoimmune diseases (8). Although sex-based 
differences in the susceptibility to autoimmune diseases are well known, the underlying 
mechanisms are not understood (9). It has been shown that sex hormones, particularly 
estrogens may contribute to the pathogenesis of some autoimmune diseases (9). The 
identification of estrogen receptors (ER) on immune cells suggested that sex steroid 
hormones, such as estrogens, may act directly on the immune system, modulating APC 
functions, lymphocyte activation and/or cytokine-gene expression. Estrogen receptors ! 
(ER!) and " (ERß) belong to the nuclear receptor family of transcription factors. They are 
encoded by two different genes Esr1 and Esr2 and account for most of the known effects of 
estrogens (10). Human and mouse DCs express transcripts for both ER isotypes (11, 12) and 
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could therefore represent a critical target for estrogens in vivo. Indeed, it has been shown that 
differentiation of DCs from murine bone marrow (BM) cells in the presence of GM-CSF was 
dramatically dependent on the presence of estrogens normally found in conventional culture 
medium (12). However, direct evidence for a role of ER! and/or ß-signaling in this effect was 
still lacking.  
In this study, we have attempted to elucidate the respective role of ER! and ERß on 
GM-CSF-induced DC development and acquisition of effector functions, using recently 
generated ER-deficient mice (13). We confirmed the requirement for estrogens to generate 
optimal number of fully functional DCs in vitro, and we demonstrated that E2 effect on DC 
differentiation was dependent on ER! but not ERß activation. The quantitative defect in DC 
development observed in the absence of ER!-signaling was also associated with phenotypic 
and functional differences, as assessed by expression of maturation markers, ability to 
stimulate T cell proliferation or to secrete pro-inflammatory cytokines in response to TLR- or 
CD40-dependent stimulations. Together these results show that E2-dependent activation of 
ER!, but not ERß, regulates critical steps involved in the development and acquisition of 
effector functions of DCs. 
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Materials and methods 
Mice 
Female C57BL/6 (B6) (H-2
b
, CD45.2) mice were purchased from Centre d’Elevage R. 
Janvier (Le Genest St Isle, France). ER!-deficient B6 mice (CD45.2) which have a deletion in 
the exon 2 of the ER-! gene (ER!-/-), ER-ß-deficient B6 mice (ERß-/-) and littermate controls 
on B6 background have been previously described (13). Females were used in most 
experiments with ER-mutant mice but identical results were obtained with males. CD45.1 
B6.SJL congenic mice were initially obtained from The Jackson Laboratory (Bar Harbor, 
ME). B10.D2 ER!-/- (H-2d) mice were generated in our own animal facilities by crossing 
ER!+/- B6 mice with B10.D2 mice obtained from Harlan (UK). After three back-crosses on 
B10.D2 background, ER!+/- H-2d/d homozygotes were selected to generate B10.D2 ER!-/- or 
ER!+/+ female mice. DO11.10 transgenic mice carrying a V!2/Vß8 TCR specific for 
OVA323-339/I-A
d
 complexes (14) on BALB/c (H-2
d
) background were initially provided by 
Dr L. Adorini (Bioxell, Milan, Italy). Mice were bred and maintained in our specific 
pathogen-free animal facility. Protocols were approved by our institutional review board for 
animal experimentation.  
 
DC generation from murine bone-marrow.  
Bone-marrow derived dendritic cells (BMDC) were generated as previously described 
(15). Briefly, BM cells were flushed out from femurs and tibias. After lysis of red blood cells 
in ammonium chloride potassium (ACK), BM cells were cultured in conventional medium or 
steroid-free medium containing 20 ng/ml murine GM-CSF (PeproTech, London, UK) at 2 x 
10
5
 cells/ml in bacteriological petri dish (Greiner Bio-One, Poitiers, France). On day 3, an 
equal volume of fresh medium with 20 ng/ml GM-CSF was added to the culture and on day 6, 
half of the medium was removed and replaced by fresh medium containing 10 ng/ml GM-
 6 
CSF. Conventional medium (referred as CM) was RPMI 1640 (Eurobio, Courtabœuf, France) 
supplemented with 10 % heat-inactivated FCS (ATGC Biotechnologie, Noisy Le Grand, 
France), 1 mM sodium pyruvate, 1 % non-essential amino acids, 2 mM L-glutamine, 50 !M 
2-mercaptoethanol and 50 !g/ml gentamicin (Sigma Aldrich, Saint Quentin Fallavier, 
France). Culture medium used for experiments in estrogen controlled conditions (referred as 
SFM) contained phenol red-free RPMI 1640 (Eurobio, Courtabœuf, France) with 10 % 
dextran charcoal-treated FCS (Hyclone, Utah, USA) supplemented with 1 mM sodium 
pyruvate, 1 % non-essential amino acids, 2 mM L-glutamine, 50 !M 2-mercaptoethanol and 
50 !g/ml gentamicin (Sigma Aldrich). Cell treatments with 17ß-estradiol (E2) (Sigma 
Aldrich), with the ER antagonist ICI182,780 (Tocris, MO, US) or with DMSO vehicle were 
performed at days 0, 3 and 6 of the cultures. Total cells in the culture were recovered at day 8 
or day 9 and counted. DC yield was calculated by multiplying total cell number by the 
percentage of CD11c
+
Gr-1
-
 DC in the culture which was determined by flow cytometry as 
described below. 
For mix bone marrow cultures, BM cells from CD45.1 mice (10
5
 cells/ml) were mixed 
with equal amount of  CD45.2 ER!+/+ or CD45.2 ER!-/- BM cells (105 cells/ml) and cultured 
with GM-CSF as described previously. Expressions of CD45.1 and CD45.2 alloantigens and 
of CD11c and Gr-1 markers were assessed by flow cytometry to calculate DC yields from 
each CD45 allotypes. 
 
DC purification and stimulations 
DCs were purified from GM-CSF cultures by positive CD11c selection by 
preincubation with CD11c-specific microbeads and subsequent immunomagnetic sorting 
using minimacs columns (Miltenyi Biotec, Paris, France). Purity after enrichment was 
routinely between 80 to 95 % CD11c
+
 cells as assessed by flow cytometry. For stimulations 
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with TLR agonists, purified DCs were stimulated with LPS (Escherichia coli 0111:B4 LPS 
Ultra-Pure (Invivogen, Toulouse, France), poly I:C (Sigma Aldrich), CpG-ODN 
phosphorothioate oligodeoxynucleotide 1668 (Sigma Aldrich) or GpC-ODN control (Sigma 
Aldrich). For CD40-dependent stimulation, purified DCs were co-cultured with control mock-
transfected or CD40L (CD154)-expressing NIH 3T3 fibroblasts which were a gift of Dr. P. 
Hwu (National Cancer Institute, Bethesda, MD) and were kindly provided by Dr. C. Reis e 
Sousa (Cancer Research UK, London).  
 
Analysis of surface markers and cytokine production 
Before staining, cells (5-10 x 10
5
) were incubated 15 min at room temperature with 
blocking buffer (PBS with 1 %  FCS, 3 % normal mouse serum, 3 % normal rat serum, 5 mM 
EDTA, 1 ‰ NaN3) containing 5 !g/ml anti-CD16/CD32 (2.4G2, ATCC). For surface cell 
staining, cells were incubated for 30 min on ice with FITC-, PE-, biotin- or APC-conjugated 
monoclonal antibodies (mAbs) diluted at the optimal concentration in FACS buffer (PBS 1 % 
FCS, 5 mM EDTA, 1 ‰ NaN3). When biotinylated mAbs were used, cells were washed twice 
in FACS buffer before incubation with APC conjugated streptavidin (eBioscience, San Diego, 
CA). The following mAbs for cell surface staining were purchased from BD Biosciences (San 
Jose, CA) : anti-CD11c (HL3), anti-CD11b (M1/70), anti-Ly6C (AL-21), anti-CD86 (GL1), 
or from eBioscience: anti-CD11c (N418), anti-MHC class II (M5/114.15.2), anti-CD40 
(HM40-3), anti-CD45.1 (A20), anti-CD45.2 (104), anti-TLR4/MD2 (MTS510) or anti-CD4 
(GK1.5). Flow cytometry analysis were performed on a FACSCalibur flow cytometer (BD 
Biosciences). 
For phenotypic analysis of DC maturation and intracellular cytokine production, 
purified DCs were incubated in CM supplemented with 10 ng/ml GM-CSF and stimulated for 
18 h  with 2 !g/ml LPS. DCs were recovered by incubation for 15 min on ice with PBS 
containing 1 % FCS and 2 mM EDTA. For detection of intracellular cytokine production, 
 8 
DCs stimulated as indicated above were incubated with 10 !g/ml brefeldin A (Sigma Aldrich) 
for the last 4 h of culture. After surface staining with FITC-anti-MHCII and APC-anti-CD11c 
and fixation in PBS 1% paraformaldehyde, cells were permeabilized with 0.5 % saponin and 
intracellular cytokine staining was performed with PE-anti-IL-6 (MP5-20F3), FITC-anti-
TNF-! (MP6-XT2), PE-anti-IL-12p40/p70 (C15.6) or PE-rat IgG1 isotype control, all from 
BD Biosciences. 
For cytokine production, DCs were cultured in 96-well plates (3 x 10
4
 cells/well) and 
stimulated with 2 !g/ml of LPS, 10 !g/ml poly I:C, 1 !g/ml CpG-ODN or 1 !g/ml  GpC-
ODN control.  For CD40-dependent stimulation, DCs (6 x 10
4
 cells/well) were co-cultured 
with CD40L-transfected NIH-3T3 fibroblasts (2.5 x 10
4
 cells/well) in 96-well plates in the 
absence or presence of anti-CD154 mAb (BD Biosciences). Mock-transfected NIH-3T3 were 
used as control. To assess IL-12p70 production, 5 ng/ml IFN-# (PeproTech, London, UK) 
were added to the stimulations. Production of IL-6, TNF-! and IL-12p40 were measured in 
24 h culture supernatants and IL-12p70 in 48 h culture supernatants. Cytokines were 
quantified by two site sandwich ELISA (all mAbs were purchased from BD Biosciences). 
 
Assessment of antigen-specific CD4
+
 T cell activation 
The ability of DCs to activate Ag-specific T cells was monitored by measuring CFSE 
dilution and thymidine incorporation of OVA-specific CD4
+
 T cells from DO11.10 TCR 
transgenic mice. CD4
+
 T cells were enriched by negative selection using CD4
+
 T cell isolation 
kit (Dynal Biotech, Compiègne, France) and labeled with 5 !M CFSE as described elsewhere 
(16). CFSE labeled DO11.10 CD4
+
 T cells were incubated at 1 x 10
5
 cells per well in 96-well 
plates (Costar) with a constant number of CD11c-sorted ER!-/- or ER!+/+ B10.D2 DCs (3 x 
10
4
 cells) per well and titrated concentrations of endotoxin-free OVA protein (Sigma) or 
OVA323-339 peptide (NeoMPS, Strasbourg, France). Cells were cultured in CM at 37°C in a 
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humidified atmosphere containing 5 % CO2. After 72 h culture, cell division was assessed by 
flow cytometry. DO11.10 TCR transgenic CD4
+
 T cells labeled with CFSE were stained with 
biotinylated anti-DO11.10 clonotype KJ1.26 and PE conjugated anti-CD4. To assess CD4
+
 T 
cell proliferation, cultured were set up as above and pulsed with 1 !Ci 
3
H-TdR (40 Ci/nmol, 
the Radiochemical Centre, Amersham, UK) at 48 h. Incorporation of 
3
H-TdR was measured 
12 h later by using a MicroBeta TriLux luminescence counter (Perkin Elmer, Waltham, MA, 
USA). 
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Results 
Generation of DC from BM progenitors is impaired in absence of E2 and requires ER!-, 
but not ERß-dependent signaling.  
Culture of BM cells in the presence of GM-CSF leads to the differentiation of CD11c
+
 
myeloid DCs, expressing CD11b and high to intermediate levels of MHC class II molecules 
(15, 17). Using this culture system, it has been previously shown that the absence of estrogens 
or the presence of ER antagonists resulted in an impaired development of CD11c
+
 CD11b
int
 
DCs  that normally represent the majority of cells generated in estrogen-supplemented 
medium (12). Instead, culture of BM cells in steroid-hormone deficient medium generated 
mainly CD11c negative cells that express the myeloid differentiation marker Gr-1 and low to 
high levels of CD11b (12). In the present study, we used this culture system to determine the 
role of ER-isotypes in this effect of E2 on DC differentiation using recently generated ER!- 
or ERß-deficient mice (13). BM cells from ER!-/- or ER!+/+ littermate control mice were 
culture in conventional medium (CM) in the presence or absence of the pure ER antagonist 
ICI182,780. As shown in Fig. 1, the frequency as well as the absolute number of CD11c
+
 Gr-1
-
 
DCs that developed from ER!-/- BM cultures was reduced up to 3 to 4-fold as compared to 
wild-type BM. This quantitative defect was associated with phenotypic changes between WT 
and ER!-/- CD11c+ DCs as shown by the analysis of CD11b and MHC class II (MHCII) 
expression (Fig. 1A and C). Whereas WT CD11c
+
 DCs were mainly composed of CD11b
int
 
MHC II
int/high
 cells, CD11c
+
 cells from ER!-/- BM cultures were enriched in cells expressing 
higher levels of CD11b and low to intermediate levels of MHC II molecules (MHC II
low/int
). 
In order to control the implication of estrogens present in standard culture medium, the pure 
ER antagonist, ICI182,780 (2 x 10
-8 
M) was added to the cultures at day 0, 3 and 6 (Fig. 1A and 
B). As expected, blocking the endogenous stimulation of ER reduced the development of DCs 
from WT BM cells (Fig. 1A  and B). Furthermore, DCs generated under such conditions 
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exhibited a CD11b/MHCII phenotype indistinguishable from ER!-deficient CD11c+ cells 
(Fig. 1A). In agreement with previous works (12), similar results were obtained when DC 
were generated in steroid hormone-deficient medium (Fig. 1 C and D). Addition of E2 (10 
nM) in cultures of WT but not ER!-/- BM cells effectively restored the capacity of the bone-
marrow progenitors to generate normal numbers of DCs with the expected phenotype (Fig. 1 
C and D).  
Although our data demonstrate the obligatory role of ER! in promoting DC 
development, it has been previously suggested that ERß could also be implicated DC 
differentiation from BM precursors (12). To address this point, BMDCs were generated  from 
ERß
-/-
 or ERß
+/+
 progenitors in steroid free medium supplemented or not with E2 (10 nM). 
Absence of E2 led to an impaired development of CD11c
+
 DCs in both ERß
+/+ 
and
 
ERß
-/-
 BM 
cell cultures that exhibited a CD11b/MHCII phenotype similar to ER!-/- DCs (Fig. 2 A). 
Addition of E2 to the steroid-free cultures allowed ERß
-/- 
BM progenitors
 
to differentiate into 
DCs as efficiently as ERß
+/+
 or ER!+/+ control cells (Fig. 2A and B). Again, E2 
supplementation of ER!-/- BM cultures could not restore normal numbers of CD11c+ DCs in 
agreement with data in Fig. 1. Similar results were obtained when BMDCs were generated in 
conventional culture medium (CM) containing regular FCS and thereby E2 (Fig. 2C). 
Altogether, these data demonstrate that estrogens are required to support efficient DC 
development from BM precursors in vitro through ER!, but not ERß.  
 
Deficiency of ER! -/- BM cells to develop into DCs is a cell-autonomous feature. 
 As ER!-signaling has been shown to regulate cytokine production in myeloid cells in 
vitro (18, 19), it was important to distinguish if the impaired DC development was caused by 
a cell-intrinsic defect of ER!-signaling within the DC lineage or by an indirect effect due to 
autocrine or paracrine factors which could regulate DC development. We examined the 
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generation of CD11c
+
 DCs from either ER!+/+ or ER!-/-  Ly5.2 BM cells when co-cultured 
with equal numbers of Ly5.1 WT BM progenitors in CM supplemented or not with an excess 
of E2 (Fig. 3). As shown in Fig. 3A, the proportion of CD11c
+
 Gr-1
-
 DCs expressing the 
CD45.2 allotypic marker was reduced by more than 2-fold when ER!-/- CD45.2 BM cells 
were cultured in competition with WT CD45.1 cells. This difference was even exacerbated in 
E2-supplemented medium, indicating that high dose of E2 further promoted DC development 
in WT but not in ER!-/- BM progenitors (Fig. 3B and E). In addition, analysis of the 
CD11b/MHC II expression profile of ER!-/- DCs (CD45.2) generated in the presence of WT 
CD45.1 progenitors (Fig. 3C) exhibited a similar phenotype as ER!-/- DCs generated alone 
(see Fig. 1). To better define the DC subsets generated under these various conditions we also 
assessed the relative expression of CD11b and Ly6C among CD11c
+
 cells. Indeed, E2 has 
been shown to preferentially promote the differentiation of CD11c
+
 CD11b
int
 lacking Ly6C 
expression, whereas the proportion of CD11b
hi 
Ly-6C
+
 cells among CD11c
+
 cells was 
increased in the absence of E2 (20). We could identify CD11b
hi 
Ly-6C
+
 and CD11b
int 
Ly6C
-
 
subsets in both WT and ER!-/- DC cultures (Fig. 3D and E). The frequency of CD11bhi Ly-
6C
+ 
cells was increased in DCs developing from ER!-/- progenitors. Similar results were 
obtained when DC were generated from WT BM in the absence of E2 (not shown). Ly6C
-
 
CD11c
+
 cells expressing an intermediate and homogenous level of CD11b (CD11b
int 
Ly6C
-
) 
were the most frequent subset in the progeny of ER!+/+ BM cells. By determining the number 
of DCs generated in each combinations, we observed that the absolute number of CD11b
int 
Ly-6C
+ 
among CD45.1/CD45.2 was neither affected by the presence of a functional ER! 
gene in BM precursors nor by providing excess E2 during DC differentiation (Fig. 3E). By 
contrast, the generation of CD11b
int
 Ly-6C
-
 DCs, which represented the majority of CD11c
+
 
cells from WT BM cultures was strongly dependent upon ER!-signaling. Indeed, when co-
cultured with ER!-/- cells, ER!+/+ (CD45.1+) cells represented 75% to 87% of total CD11bint 
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Ly-6C
-
 CD11c
+
 in the absence or presence of exogenously added E2, respectively. Thus, the 
generation of CD11b
int
 Ly-6C
-
 DCs from ER!-/- BM precursors could not be rescued by WT 
hematopoietic progenitors. Reciprocally, the development of WT CD45.1 DCs was not 
affected by the presence of ER!-deficient BM cells. Altogether, these results further 
underscore a requirement for ER! activation in DC development and provide evidence for a 
cell-autonomous function for ER!-signaling in DC generation.  
  
ER!-deficient DC show phenotypic and functional abnormalities.  
DC development is decreased in absence of ER!-signaling but not abolished. The DC 
that develop in these conditions are enriched in cells expressing high levels of CD11b, Ly-6C 
and lower levels of MHC class II, that may represent immature myeloid DCs. ER!-/- DCs 
were enriched in cells expressing low to undetectable levels of MHC class II molecules and 
displaying high CD11b staining (see Fig. 1 to 3, and Fig. 4A). Although expression of 
costimulatory molecules was similar between the majority of untreated immature ER!-/- and 
control DCs, the frequency of cells expressing high levels of MHC class II and CD86 was 
higher in WT DCs than in ER!-/- DCs (Fig. 4A).  DCs were stimulated through TLR4 (LPS) 
or TLR9 (CpG-DNA) for 24 h, followed by flow cytometric assessment of surface expression 
of MHC class II, CD86 and CD40 costimulatory molecules. As expected, a strong up-
regulation of MHC class II and co-stimulatory molecules CD86 or CD40 was observed in WT 
DCs after stimulation with LPS or CpG-DNA. By contrast, despite an increased expression of 
CD40 molecules to levels similar to WT DCs, about 30% to 50% of ER!-/- DCs failed to 
upregulate MHC class II or CD86 molecules upon stimulation through TLR4 or TLR9 (Fig. 
4A). Thus, as for MHC class II molecules, upregulation of CD86 was significantly impaired 
in some ER!-/- DCs in response to LPS or CpG. By contrast, no major defect in CD40 
expression was observed after LPS- or CpG-induced maturation of ER!-/- DCs. 
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 We also measured IL-6 and IL-12 production by DCs stimulated with  poly I:C 
(TLR3), LPS , CpG-DNA in the presence or absence of IFN-#. As shown in Fig. 4B, ER!-/- 
DCs stimulated with LPS or poly I:C secreted more IL-6 and TNF-! (not shown) than WT 
DCs, whereas cytokine production in response to CpG was slightly reduced in ER!-/- DCs 
(Fig. 4B). Likewise, in the presence of IFN-#, IL-12p70 secretion was again superior in ER!-/- 
DC cultures stimulated with LPS or polyI:C as compared to WT DCs. Thus, despite some 
defects in their maturation processes ER!-/- DCs exhibited an enhanced capacity to produce 
various pro-inflammatory cytokines in response to microbial components that trigger DCs 
through TLR4 or TLR3. This observation was confirmed by single cell analysis of IL-6 and 
TNF-! production by intracellular staining after LPS stimulation. DCs producing either IL-6, 
TNF-! or both, were more frequent in CD11c+ ER!-/- DCs stimulated by LPS (Fig. 4C). This 
enhanced LPS-responsiveness of ER!-/- DCs was correlated with an increased frequency of 
cells expressing high levels of TLR4 and CD11b molecules (Fig. 4E). 
 
T cell stimulatory capacity of ER! -/- DCs is impaired. 
Because the principal function of DC is to activate T lymphocytes, we next evaluated 
the ability of ER!-/- DCs to prime OVA-specific naive CD4+ T cells from DO11.10 Tg mice. 
For this purpose the ER!-mutation was back-crossed to B10.D2 mice to generate ER!-/- mice 
of the H-2
d
 haplotype.  The defect in BMDC development was identical between B10.D2 and 
C57BL/6 ER!-deficient mice (data not shown). DCs were generated from B10D2 ER!-/- or 
ER!+/+ mice and CD11c+ purified DCs were then used to stimulate transgenic DO11.10 CD4+ 
T cells which express a TCR specific for the I-A
d
/OVA323-339 peptide complex. The 
proliferative capacity of DO11.10 CD4
+
 T cells was significantly impaired when ER!-/- DCs 
were used as APCs in response to both OVA323-339 peptide (Fig. 5A and B) or OVA protein  
(Fig. 5C and D). We next determined whether the defective capacity of ER!-deficient DCs to 
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prime OVA-specific CD4
+
 T cell proliferation was due to lack of E2-mediated signaling 
during DC development. B10.D2 DCs were generated in steroid-free medium supplemented 
or not with various doses of E2. Purified DCs were then tested for their capacity to activate 
DO11.10 T cells in the presence of OVA323-339 peptide. As shown in Fig. 5E, WT DCs 
generated in the absence of E2, like ER!-deficient DCs, exhibited a reduced capacity to 
induce the proliferation of DO11.10 CD4
+
 T cells. This functional defect was reversed by 
adding exogenous E2 to WT but not to ER!-/- DCs. Indeed, when DCs were generated in the 
presence of doses ranging from 0.1 to 10 nM, they were able to efficiently activate naive 
CD4
+
 T cells (Fig. 5E and data not shown). This was confirmed by analyzing CFSE dilution 
in DO11.10 T cells (data not shown). E2 at 0.01 nM or below could not support efficient DCs 
development and DCs generated  in this conditions had a phenotype similar to ER!-/- DCs 
(data not shown).  
 
DCs that develop in the absence of ER-signaling have reduced cytokine response to 
CD40 triggering. 
 Because DC effector functions are markedly dependent on T cell-derived signal (5, 6), 
we assessed the effect of CD40 ligation on the cytokine response of WT or ER!-/- DCs. We 
showed that CD40 expression was similar between immature WT and ER!-/- DCs and was 
strongly upregulated in both DC populations upon stimulation with LPS or CpG (Fig. 4). We 
next evaluated the capacity of DCs to respond to CD40-dependent signaling. Culturing WT 
DCs on a monolayer of CD40L-expressing fibroblasts, but not control cells (not shown), 
induced high levels of IL-6 and IL-12p40 (Fig. 6A). In contrast, cytokine production was 
strongly reduced in ER!-/- DCs upon CD40 triggering  (Fig. 6A). Addition of an excess of E2 
during DC development resulted in an enhanced production of IL-6 and IL-12p40 in WT but 
not in ER!-/- DCs (Fig. 6 B). Similar results were obtained upon CD40L-stimulation in the 
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presence of IFN-# (Fig. 6C). In addition to IL-6, high levels of IL-12p70 were induced in WT 
DCs, but not in ER!-/- DCs. Cytokine production by DCs was blocked  in the presence of 
anti-CD154 antibody (Fig. 6C). 
 We then determined the frequency of IL-12p40-producing cells by intracellular 
staining of DCs stimulated with CD40L-transfected fibroblasts for 18 h. Compared with 
baseline staining with an isotype control mAb, 10% to 25% of WT DCs could be stained for 
IL-12p40 (Fig. 6D and data not shown). By contrast the frequency of IL-12p40-producing 
cells was reduced by 3 to 10-fold in ER!-/- DCs (Fig. 6D and data not shown). Cytokine-
producing cells were contained in DCs expressing high levels of MHCII in both CD40L-
stimulated WT and ER!-/- DCs. DCs that had upregulated MHCII molecules (MHCIIhi) had 
also increased their expression of CD40 when compare to MHCII
low
 DCs. Notably, no 
difference were seen between WT and ER!-/- DCs, which indicates that defective CD40L-
mediated activation of ER!-/- DCs can not be explained by a reduced expression of CD40 
molecules.   
 Finally, we evaluated whether the functional differences we observed in ER!-/- DCs 
were also found in DCs generated from WT progenitors in the absence of estrogens. Purified 
WT DCs generated in steroid-free medium supplemented or not with E2 were activated for 24 
h with LPS (Fig. 7A and B) or CD40L-transfected cells (Fig. 7 C and D) in the absence (Fig. 
7, A and C) or presence of E2 (Fig. 7, B and D). As shown in Fig. 7A, IL-6 synthesis was 
strongly enhanced in LPS-stimulated ER!-/- DCs but also in WT DCs generated in the 
absence of E2 (E2-deprived DCs) as compared to WT DCs generated in E2-supplemented 
medium. When stimulated through CD40, again ER!-/- DCs and E2-deprived WT DCs had an 
identical phenotype and produced significantly less IL-6 as compared to E2-supplemented 
WT DCs (Fig. 7C). Similar cytokine profiles were observed when DC stimulations were 
performed in E2-supplemented medium (Fig. 7, B and D). Thus, the presence of the hormone 
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at the time of TLR- or CD40-mediated stimulation had little if any effect on cytokine 
production by DCs. These results are consistent with an E2 action, through ER!, on precursor 
cells during DC development rather than on already differentiated cells. 
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Discussion  
In the present study, we confirm that estrogens are critical to support normal DC 
development from BM precursors (12), and unambiguously establish that ER!, but not ER", 
is required to mediate this effect. Indeed, DCs generated from WT precursors grown in 
steroid-free conditions were indistinguishable from DCs derived from ER!-deficient 
precursors, irrespective of the presence or absence of E2. ER!-deficient DCs showed an 
impaired capacity to upregulate MHC class II and CD86 molecules upon TLR stimulation and 
to activate naive CD4
+
 T cells. Failure of ER!-/- DCs to efficiently prime CD4+ T cells was 
associated with a reduced ability to produce pro-inflammatory cytokines in response to 
CD40L. Thus, E2-dependent activation of ER!, but not ERß, regulates critical steps involved 
in DC development in vitro. 
It has been previously shown by Kovats and co-workers that estrogens were required 
to promote DC differentiation from bone-marrow progenitors, but the respective roles of ER! 
and ER" in this effect remained unresolved (12). Noteworthy, Kovats’s group previously used 
a first generation model of ER!-targeting mice, consisting in the insertion of a Neo-cassette 
into exon 1 hereafter called ER!-Neo-/- (21).  Although the development of DCs from ER!-
Neo
-/-
 mice was impaired, addition of excess of E2 restored near normal numbers of CD11c
+ 
CD11b
int
 cells in the cultures, suggesting a possible compensatory role of ERß (12). The 
explanation of this apparent discrepancy resides most likely in the recently characterized 
phenotypic difference between these two mutant strains. Although the expression of the full 
length 66 kD isoform of ER! (p66) is abolished in ER!-Neo-/- mice, two others splice 
variants lacking the AF-1 transactivator domain have been identified (p55, p46) which still 
possess a residual estrogen-dependent transcriptional activity (22-24). By contrast, in the 
mouse model of complete inactivation of ER! used in the present study (13, 22) E2, even in 
high amounts, failed to promote DC differentiation from BM progenitors, demonstrating that 
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ERß-signaling could not compensate for the lack of ER!. Thus, our results show for the first 
time that ER! is the main receptor implicated in the E2-dependent differentiation of BM 
progenitors into DCs in vitro. These data also suggest that the AF-1 transactivator domain of 
ER! might be dispensable for the E2-mediated effect on DC development as it was 
previously shown for some vascular effects of E2 (22).  
 Myeloid progenitors (MP) can be distinguished into several subsets according to 
CD34 and CD16/32 expression, among them a CD34
+
 CD16/32
+
 common precursor for both 
macrophages and tissue resident DCs (MDP) has been recently identified, based on the 
expression of CX3CR1 (25). We showed that inhibition of ER! activation in WT BM cells 
during DC differentiation led to a phenotype similar to that of ER!-/- cells excluding specific 
myeloid precursor deficiency due to lack of estrogen-signaling in ER!-/- mice in vivo. 
Moreover, it was previously shown that E2 had maximal effect at the beginning of the culture, 
consistent with E2 action on precursor cells (12). In addition, impaired DC development 
persisted when ER!-deficient progenitors were co-cultured with WT cells, indicating a cell-
intrinsic requirement for ER! activation. Likewise, the generation of WT DC was not 
affected by the presence of ER!-deficient progenitors. Thus, default DC development from 
ER!-/- progenitors was intrinsic to the cells and not due to autocrine or paracrine effects of 
cytokines present in the microenvironments. Activated ligand-bound ER classically leads to 
genomic effects. Transcriptional responses to estrogens were initially recognized to depend on 
specific interaction of activated ER with ERE sequences in the promoter of target genes, but 
interaction of ER with other transcription factor complexes, like AP-1 (26) or Sp-1 (27), are 
common modulating mechanisms of their transcriptional activity. Although the transcription 
factor families AP-1 and Sp-1 are ubiquitously expressed, they are known to regulate several 
myeloid-specific gene expression (28, 29). Our current hypothesis is that E2-dependent 
activation of ER! might regulate the activation state or expression level of transcription 
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factors implicated in DC lineage commitment at early stages during differentiation of BM 
precursors (30). Interestingly, it has been recently shown that E2 acts directly on highly 
purified myeloid progenitors, including MDPs (25), to regulate GM-CSF-induced DC 
differentiation (31). 
We confirmed that the development of the principal DC subtype CD11b
int
 MHC
int
 
Ly6C
neg
 was primarily impaired in the absence of ER!-signaling, whereas the development of 
CD11c
+
 cells expressing high levels of CD11b and Ly6C and low levels of MHCII was 
spared. This estrogen insensitive subset might correspond to a monocyte/macrophage-like 
population usually present at low frequency in WT BMDC cultures (15, 32). Indeed, we 
observed an 2 to 3-fold increase in macrophage-like cells in ER!-/- DC cultures by cytological 
staining (data not shown). This observation correlated with an increased frequency of cells 
expressing high levels of TLR4-MD2 active complexes and CD11b in ER!-/- DCs or in 
estrogen-deprived WT BMDC, in agreement with previous work (20). This could explain the 
higher propensity of ER!-/- DCs to produce cytokines upon LPS stimulation as both TLR4 
and the ß2 integrin CD11b have been shown to act in concert to positively regulate MyD88-
dependent LPS signaling in macrophages (33, 34). The commitment of myeloid progenitors to 
DCs vs. macrophages could be therefore differentially regulated by E2-signaling under GM-
CSF-induced differentiation. It has been proposed that high PU.1 activity could favor DC at 
the expenses of macrophage fate through the negative regulation of the macrophage specific 
transcription factor Maf-B (35). ER!-signaling during DC development could therefore 
regulate the balance between PU.1, Maf-B or others transcription factors (30), thereby 
modulating DC differentiation.  
The capacity of DCs to respond to T-cell dependent signals is critical to initiate 
adaptive immune responses and drive Ag-specific CD4
+
 T cell activation and differentiation 
through CD40-dependent production of polarizing cytokines such as IL-12, IL-23 and IL-6 
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(36). Our data clearly showed that DCs generated in the absence of E2 or ER!-signaling 
exhibited an impaired capacity to activate naive CD4
+
 T cells as compared to DCs generated 
in the presence of E2. The low level of MHC II and CD86 costimulatory molecule expressed 
by the main CD11b
high
 DC subsets from ER!-/- or E2-deprived WT cultures can partly 
account for their inability to prime CD4
+
 T-cell proliferation. Additionally, we found that E2-
dependent ER! activation during in vitro DC differentiation enhances CD40-dependent 
production of IL-12 and IL-6, two important polarizing cytokines that drive expansion of 
naive CD4
+
 T cells to the Th1 or Th17 pathway, respectively (36). By contrast, E2 treatment 
on already differentiated DCs during stimulation with TLR- or CD40- ligands did not 
significantly modify cytokine secretion profiles. Thus, despite numerous studies showing that 
estrogens could inhibit NF-kB and suppress pro-inflammatory cytokine expression in myeloid 
cells in vitro (18, 19, 37), we were unable to document any significant inhibitory effect of E2 
on either TLR- or CD40- dependent cytokine production by DCs. Thus differential cytokine 
production between DCs that developed in the absence or presence of E2-signaling is 
imprinted during GM-CSF-induced differentiation and therefore reflects an E2 effect on 
precursors or developing DCs rather than on already differentiated cells.  
Generation of conventional GM-CSF-induced BMDC is usually performed in culture 
medium exhibiting an estrogenic activity (estrogens present in standard FCS but also the pH 
indicator phenol red). Interestingly, addition of wide dose range of E2 from 0.1-10 nM in 
steroid free medium could restore DC development and in conventional medium could further 
increase CD40-dependent cytokine production. Concentrations of E2 between 0.1-1 nM 
correspond to physiological levels of E2 found in adult female mice, during diestrus (20-35 
pg/ml) and estrus (100-200 pg/ml), respectively (38), suggesting that low levels of E2 could 
potentially modulate immune responses in vivo. Indeed, we have shown that administration of 
E2 in castrated C57BL/6 (B6) mice resulted in a marked upregulation of antigen-specific CD4 
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T cell responses and in the selective development of IFN-#-producing cells, through ER!-
signaling in hematopoietic cells (39). Interestingly, E2 has been also shown to selectively 
enhance IFN-#-production by NKT cells in vivo (40). Furthermore, E2 treatment was also 
shown to enhance the susceptibility to experimental autoimmune myasthenia gravis (EAMG) 
a Th1-dependent B cell-mediated autoimmune disease (41). Whether this effect of E2 in vivo 
is due to a direct modulation of DC development and/or function remains however to be 
investigated. Understanding further the impact of ER-signaling on DC biology may therefore 
provide new insights into the mechanisms by which sex-linked factors affect immunity and 
susceptibility to autoimmune diseases in women.  
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Figure legends 
 
Figure 1. ER!  activation is critical for BMDC generation. ER!-/- or ER!+/+ BM cells were 
grown for 9 days with GM-CSF in conventional medium (CM) with (A, B) ± 20 nM ICI182,780 
or in steroid-free medium (SFM) supplemented or not with 10 nM E2 (C, D). The percentages 
of CD11c
+
Gr-1
-
 and CD11b
int
MHCII
+
 cells of gated CD11c
+
 cells were determined by flow 
cytometry and are indicated. Absolute number of  DCs generated in CM (B) or in SFM (D) 
are reported as the mean and the SEM of five to seven independent experiments. Differences 
between variables were evaluated by the Mann-Whitney U test (**, p < 0.01; ns, not 
significant).   
 
Figure 2. ERß activation is dispensable for BMDC differentiation. (A) ER"-/- or ER"+/+ 
BM cells were grown for 9 days with GM-CSF in SFM ± 10 nM E2. The percentages of 
CD11c
+
Gr-1
-
 and CD11b
int
MHCII
+
 cells of CD11c
+
gated cells were determined by flow 
cytometry and are indicated. Absolute numbers of DCs generated from ER!-/- or ER"-/- BM 
cells in SFM (B) or in CM (C) supplemented with 10 nM E2 are expressed as the mean and 
the SEM of triplicate or quadruplicate cultures. Data are representative of three experiments.  
 
Figure 3. Intrinsic expression of ER!  is required to promote BMDC development. (A, 
B) CD45.2 BM cells from ER!-/- or ER!+/+ mice (3 mice per group) were cultured in 
competition with CD45.1 BM cells at 1:1 ratio in CM alone or supplemented with 10 nM E2.  
(A) Percentages of CD45.1 positive and negative (CD45.2
+
, not shown) cells gated on 
CD11c
+
Gr-1
-
 DCs are indicated. (B) Ratio between the frequency of CD45.1 and CD45.2 
DCs (defined above as CD45.1
-
 DCs) in each combinations are indicated. Data are expressed 
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as mean ± SEM of three mice per group. Data were analyzed for statistical significance with a 
two-tailed Student’s t test (**, p < 0.01). (C and D) The expression of phenotypic (CD11c, 
Gr-1, CD11b, MHCII, Ly6C) and allotypic CD45.1 markers was analyzed in competition 
experiment performed as in panel A. The percentages of CD11b
int
MHCII
+
 (C) and 
CD11b
+
Ly6C
-
 or Ly6C
+
 DCs (D) among WT CD45.1 and ER!-/- CD45.2 DCs are shown. (E) 
The absolute numbers of CD11b
+
Ly6C
-
 and CD11b
+
Ly6C
+
 DCs generated from WT CD45.1 
BM cells cultured in competition with ER!-/- or control ER!+/+ CD45.2 BM cells are 
indicated. Culttures were performed in CM alone or supplemented with an excess of E2 as 
indicated. Numbers in parenthesis indicate the ratio between CD45.2 and CD45.1 DCs. Data 
are representative of three independent experiments. 
 
Figure 4. ER! -/- BMDCs are phenotypically and functionally distinct from WT BMDCs. 
ER!+/+ or ER!-/- BMDCs were generated in CM as in Fig.1 and were purified by CD11c 
positive selection. (A) DCs were left untreated (filled histogram) or stimulated for 18 h with 
TLR ligands as indicated (open histogram). Expression of MHC-II, CD86 and CD40 were 
analyzed by flow cytometry. (B and C) ER!+/+ or ER!-/- DCs were stimulated with Poly(I:C), 
LPS or CpG DNA in absence (B) or in presence of IFN-#. IL-6 and IL-12p70 were measured 
by ELISA in 24 h (B) or 48 h (C) culture supernatants, respectively. Results are expressed as 
the mean and the SEM of three mice per group. Data were analyzed for statistical significance 
with a two tailed Student’s t test (*, p < 0.05; **, p < 0.01). (D) DCs were stimulated with 
LPS (2 !g/ml) for 18 h and were assessed for IL-6 and TNF-! production by intracellular 
staining. Dot plots show IL-6 vs. TNF-! staining of gated CD11c+ cells. (E) Dot plots show 
CD11b vs. TLR-4 expression of resting CD11c
+
 ER!+/+ or ER!-/- DCs. Data are 
representative of three to four independent experiments. 
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Figure 5. ER!-activation during DC development enhances the CD4+ T cell-priming 
capacity of DCs. Purified CD11c
+
 ER!+/+ or ER!-/- BMDCs generated in CM as in Fig. 1 
were loaded with OVA323-339 peptide (A, B) or with OVA protein (C, D) to stimulate naive 
transgenic DO11.10 CD4
+
 T cells. Histograms show CFSE intensity of KJ1.26
+ 
CD4
+
 T cells 
after 72 h stimulation (A,C). Results are expressed as percentage of dividing cells among 
KJ1.26
+
 CD4
+
 T cells (B, D) and are representative of three independent experiments. (E) 
BMDC cultures were conducted in SFM supplemented or not with the indicated doses of E2. 
ER!+/+ or ER!-/- CD11c+ DCs were purified and were loaded with 0.1 !M OVA peptide to 
stimulate DO11.10 CD4
+
 T cells. CD4
+
 T cell proliferation was assessed by 
3
H-thymidine 
incorporation during the last 12 h of culture. Results are presented as the mean and the SEM 
of quadruplicate cultures and are representative of three to four independent experiments. 
 
Figure 6. ER ! -/- BMDCs exhibit impaired production of pro-inflammatory cytokines in 
response to CD40 triggering. (A) Purified CD11c
+
 BMDCs from ER!+/+ or ER !-/- mice 
were cultured on a monolayer of CD40L-expressing fibroblasts. IL-6 and IL-12p40 were 
measured by ELISA in 24 h culture supernatants. Data are expressed as the mean and the 
SEM of four mice per group and were analyzed for statistical significance with a two tailed 
Student’s t test (*, p < 0.05; **, p < 0.01). (B) E2 (10
-8 
M) was added or not during BMDC 
differentiation in CM and the production of IL-6 and IL-12p40 by CD40L-stimulated DCs 
was tested as above. (C) DCs (30 x 10
3
 DCs per well) obtained as in (B) in CM + E2 from 
ER!+/+ or ER !-/- BM cells were cultured on a monolayer of CD40L-expressing fibroblasts 
with IFN-# (5 ng/ml) to measure IL-6 and IL-12p70 production in 24 h culture supernatants.  
Anti-CD154 mAb was added to the cultures at the indicated doses. (D) DCs obtained as in (C) 
were stimulated during 18 h with CD40L-expressing cells. Cells were stained with mAb 
specific for CD11c, CD40 and MHC class II and fixed for intracellular analysis of IL-12p40 
 31 
production by flow cytometry. Left, Dot plots show IL-12 p40 vs. MHC II of gated CD11c
+
 
DC. Right, expression of CD40 on MHC II
high 
or MHC II
low
 CD11c
+
 DCs. Results are 
representative of two to three independent experiments. 
 
Figure 7. ER!  activation during DC development controls the acquisition of specific 
effector functions. ER!+/+ BM cells were cultured for 9 days in SFM supplemented with 10 
nM E2 (filled circle) or with vehicle (DMSO, open circle). ER!-/- BMDCs were generated in 
SFM + 10 nM E2 (open triangle). Purified CD11c
+
 DCs were stimulated with LPS (A, B) or 
CD40L-transfected cells (C, D) in SFM (A, C) or SFM supplemented with 10 nM E2 (B, D). 
IL-6 production was measured in 24 h-culture supernatants by ELISA. Results are presented 
as the mean ± SEM of triplicate cultures and are representative of three experiments.  
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